Examination of genomic and proteomic changes associated with ras-driven epithelial to mesenchymal transformation (EMT) of polarized epithelial cells has led to an improved understanding of surface-expressed structures and alterations in components involved in intracellular trafficking events that are altered as normal cells become cancerous. We have identified a mechanism involved in the establishment of cell-cell contracts known as tight junctions (TJs) which involves the orchestrating actions of the protein occludin (Ocln) and its ability to reverse EMT events. A screen for agents to re-activate suppressed occludin (OCLN) gene function caused by Ras/Raf/MEK/ERK pathway activation has led to the identification of several small molecules that can reverse cellular changes associated with EMT. Additionally, we had previously observed the up-regulation of a cell-surface expressed import system for small peptides, hPepT1, in pancreatic cancer cells which are known to be to be driven by the Ras/Raf/MEK/ERK pathway. We now describe two approaches to identify agents capable of re-activating Ocln expression which could be modified to be selectively absorbed by cancer cells which over-express functional hPepT1. Using this combined information of a drug that functions only in cancer cells having reduced Ocln expression with an up-regulated uptake mechanism that correlates reduced Ocln expression, we believe that it is possible to identify improved cancer chemotherapies that have reduced off-target drug distribution and thus great functional targeting.
ABSTRACT
Examination of genomic and proteomic changes associated with ras-driven epithelial to mesenchymal transformation (EMT) of polarized epithelial cells has led to an improved understanding of surface-expressed structures and alterations in components involved in intracellular trafficking events that are altered as normal cells become cancerous. We have identified a mechanism involved in the establishment of cell-cell contracts known as tight junctions (TJs) which involves the orchestrating actions of the protein occludin (Ocln) and its ability to reverse EMT events. A screen for agents to re-activate suppressed occludin (OCLN) gene function caused by Ras/Raf/MEK/ERK pathway activation has led to the identification of several small molecules that can reverse cellular changes associated with EMT. Additionally, we had previously observed the up-regulation of a cell-surface expressed import system for small peptides, hPepT1, in pancreatic cancer cells which are known to be to be driven by the Ras/Raf/MEK/ERK pathway. We now describe two approaches to identify agents capable of re-activating Ocln expression which could be modified to be selectively absorbed by cancer cells which over-express functional hPepT1. Using this combined information of a drug that functions only in cancer cells having reduced Ocln expression with an up-regulated uptake mechanism that correlates reduced Ocln expression, we believe that it is possible to identify improved cancer chemotherapies that have reduced off-target drug distribution and thus great functional targeting.
INTRODUCTION
While the actual basis for metastasis is currently unclear (1) , the impact of this event is clear: the majority of cancer-related deaths, up to 90%, can be attributed to disseminated disease rather than the impact of the primary tumor (http://www.cancerquest.org/metastasis-overview.html). At least half of the patients diagnosed with cancer present with clinically detectable metastatic disease (2) . For these reasons, metastasis is considered the most life-threatening event in patients with cancer (3) . Thus, strategies to selectively target disseminated disease have become a primary focus of drug delivery efforts. A standard approach to target these disseminated cancer cells is to use an agent that selectively targets to cancer cells to deliver a toxic payload; primarily antibodies that recognize a cancer-associated structure. It is clear, however, that previous efforts to selectively target cancer cells following systemic administration for the focused delivery of therapeutic agents have resulted in only a small fraction of these materials reaching metastatic sites (4) . These approaches, while delivering measurable amounts of potent cytotoxic agents to intended sites typically result in substantial exposure of these agents to non-cancerous tissues as well.
Epithelial to mesenchymal transformation (EMT) is a reversible event, and that reversion is known as mesenchymal to epithelial transformation (MET). We have examined an underlying cellular pathway known to control endogenous mechanisms used by epithelial cells to transition between differentiated and mesenchymal formats in wound repair, replacement of senescent cells, etc (5) . Importantly, the Ras/Raf/MEK/ERK pathway selected for our studies not only functions in reversible EMT↔MET process but has also been shown to drive oncogenic conversion following its un-regulated activation (6) . We have taken the approach that epithelial cancers are a manifestation of cells driven into EMT, but that, for a variety of reasons, fail to transition back through MET into differentiated epithelial cells. Further, cellular events that "lock" epithelial cells in an oncogenic state might be reversible if the correct cellular "key' was identified. The approach taken in this report describes efforts made to find such a "key" and the equally important issue of finding a means to allow that key to efficiently find the "lock" in an oncogenic epithelial cell. We believe that this concerted approach could lead to novel strategies to selectively modify cancer cell function, allowing for less cytotoxic methods to control these aberrant cells.
The first step to explore this strategy was to identify a cell-specific target that was critical in the reversible EMT↔MET processes that are also known to be un-regulated in epithelial cancers. It is critical that the EMT↔MET pathway process is understood sufficiently to allow transition of oncogenic epithelial cells back into a differentiated format. We had previously observed that epithelial cells driven to an oncogenic state by constitutively active Raf will down-regulate proteins involved in cell-cell interactions that function to signal the presence of and interaction with an adjacent epithelial cell. While most proteins involved in these cell-cell contacts were suppressed at the protein expression level, only one was observed in our model to be affected at the message level: occludin (Ocln). The significance of this observation is supported by studies showing that reduced levels of Ocln expression correlated with increased cancer progression (7) (8) (9) . Importantly, forced expression of Ocln protein in the presence of continued expression of activated Raf could reverse the oncogenic phenotype and retrieve a functional epithelial cell (10) .
Since that initial demonstration, much has been learned about the Raf/Ocln dynamic and the role played by Ocln as a counter-balance to the Ras/Raf/MEK/ERK pathway.
Suppression of the Ras/Raf/MEK/ERK pathway can restore differentiated phenotype and functional TJs in a variety of cells types including transformed canine kidney cells (11) , human corneal cells (12) , mouse hepatocytes (13) , and medullary thyroid carcinoma cells (14) . Epigenetic silencing of OCLN promotes tumorigenic and metastatic properties of cancer cells involving and re-activation of endogenous Ocln expression makes these cells more susceptible to the induction of apoptosis (15) .
Further, Ocln functions to control premature senescence events; its forced expression in breast cancer cells induces anoikis and promotes senescence following oxidative stress (16) . Overall, these observations support the possibility that inducing Ocln reexpression in cancer cells could lead to increased sensitivity of these cells to agents that could induce cell death via apoptosis and/or senescence pathways (15, 16) , leading to a more focused and less toxic therapeutic approach.
The second aspect of our approach requires the identification of a specific target in cancer cells that can be selectively "unlocked" using some pharmacological agent. In our case, we looked for a means to re-activate Ocln expression. Previous studies have shown that Hela cells treated with retinoic acid receptor α (RARα) agonists or treated with a de-methylating agent followed by a histone deacetylase inhibitor can re-express endogenous Ocln (16 (19) . Up-regulated hPepT1 has also been observed on pancreatic, prostatic, and gastric cancer cells and its function appears to be important for cell survival (20, 21) , suggesting a critical role for hPepT1 expression in these cancer cells.
Previous studies have demonstrated that small molecule can be made into hPepT1
substrates by chemical coupling to certain amino acids (22) (23) (24) , suggesting that a variety of molecules identified in our studies might be made into a selective hPepT1 substrate.
Based upon the approach outlined above, we have examined two separate screening strategies to identify agents capable of re-activating OCLN expression and which might be made into hPepT1-selective substrates. One strategy used a phage display strategy to identify small peptides capable of disrupting Slug binding to the OCLN promoter.
The other strategy was cell-based, using a cancer cell line stably expressing a reporter gene constructed from the open reading frame of luciferase and the OCLN promoter.
Together, these screening strategies have provided an initial assessment for the feasibility of our approach to identify reversible EMT↔MET process that can be regulated in-synch with agents that affect these processes and which could be selectively targeted based upon concurrent cellular modifications. 
MATERIALS AND METHODS

Phage
Assaying for Slug protein binding to E-box DNA.
The procedure for assaying Slug binding to E-box DNA is shown in Figure 1 . Briefly, DNA oligoduplexes used in affinity selection of phage-displayed peptides and in Slug binding assays were annealed as described above. 96-well plates were coated with streptavidin (10 μg/ml, 100 μL/well) at 
Generation of stable cell lines.
The pOccRluc and control constructs pRluc and pcDNA3.1 were transfected into human non-small lung carcinoma cell line H460 and cervix adenocarcinoma cell line Hela (ATCC) using transfection reagent Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocol. Stable cell lines were selected in 500 μg/mL hygromycin, validated for the integration of the chimeric gene into the cell genome by genomic PCR, and maintained in DMEM medium supplemented with 300 μg/mL hygromycin.
Integration of plasmid pOccRluc was further functionally verified by treating the cells with MEK inhibitor PD98059 which resulted in increased luciferase expression using a commercial kit (Promega).
Compound screening protocols.
Cell-based reporter screening system. H460-pOccRluc, along with positive control H460-pRluc, and negative control H460-pcDNA3.1 cells were seeded at 8000 cells/well in 100 μL DMEM complete medium in 96-well white with clear bottom plates. Plates were made up in triplicate, seeded on day 1, treated on day 2 with test compounds, and assayed on day 4. Test compounds were tested at 5 μM, being added in DMSO (final concentration of 0.4%); with control wells receiving an equivalent amount of DMSO. The addition of DMSO to some wells was also used to serve as a negative control. After 48 hr of test compound exposure, the medium was aspirated, and cells were lysed with 30 μL/well fresh-prepared lysis buffer (150 mM HEPES, pH 8.0, 0.05% Triton X-100, 1 mg/ml Porcine Gelatin, pH 7.6, 10% Glycerol) at room temperature for 10 min with shaking. 30 μL of 1X Renilla luciferase assay substrate working solution (0.01 mg/ml Renilla luciferase assay substrate Coelenterazine, 5M NaCl, 0.5M KH2PO4, 0.1M EDTA, pH 8.0, 1mg/ml Porcine Gelatin, pH7.6) was then added to each well and luminescence was read immediately using a luminometer (BioTek).
Protein-based screening system. Test compounds were first incubated in binding solution with E-box DNA or control biotin-labeled oligoduplexes. After addition to steptavidin-coated plates, these oligoduplexes were exposed to eight ug of GFP-Slug.
After washing with washing buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1% Tween-20), the presence of materials capable of competing for the Slug binding site on the occludin promoter E-box was monitored by the lack of or reduced fluorescent signal for bound GFP-Slug using a fluorimeter. Biotin-labeled E-box oligoduplexes without test compounds served as a positive control, while a mutant E-box sequence lacking the ability to bind Slug (17) 
Assay of selected peptides for competitive inhibition of Slug binding to E-box DNA.
After the validation of selected peptide phages for target binding by ELISA, identified E-box-binding peptide variants were synthesized by American Peptide Co., and tested for their ability to compete with Slug for binding to the E-box DNA. Specifically, biotinylated E-box DNA, each peptide to be characterized, and Slug protein were incubated in binding buffer on ice for 30 min. The mixtures were transferred into plates coated with strepavidin and incubated at room temperature for 1 h. The captured peptide-DNA or Slug-DNA complexes were washed 3 times and detected as described above. In another experiment, Slug and E-box DNA were first incubated on ice for 30 min, the testing peptides were added, and then the ability of the peptides to remove Slug from the E-box DNA was determined as described above.
HYPOTHESIS AND RATIONALE OF STUDIES
Hypothesis behind strategy to find agents to rectify cell-cell contacts. Normal epithelia undergo dynamic changes that involve transient periods of de-differentiation that allows for mitosis and cell migration followed by differentiation to re-establish functional barriers (Fig 1A) . Such events are essential for development, wound repair, and replacement of senescent cells. Our hypothesis centers on the idea that epithelial cancer cells have entered into the de-differentiation pathway but have lost the ability to re-establish functional barriers required for re-establishment of a differentiated phenotype (Fig 1B) . A variety of factors could block the re-establishment of functional barriers that drive differentiation (27) . We have focused on identifying ways to reverse EMT events with the outcome of potentially overcoming drug resistance to various anti-cancer agents (28) or making cancer cells significantly more susceptible to these agents. In the present studies we have focused on the mechanism used by active raf to downregulation of tight junction (TJ) structures, with particular attention on the TJ protein Ocln which appears to have orchestrating capability in the formation of nascent TJs (10) . Using an epithelial cell model, we have determined that activation of the Ras/Raf/MEK/ERK pathway results in an increase in function of the repressor protein Slug which directly blocks OCLN transcription to maintain epithelial cells in a dedifferentiated form (17) . As a result of this de-differentiation, epithelial cells should express a distinct set of surface elements, some of which might be used to target prodrug agents to these non-polarized cells following systemic administration. We had examined potential uptake mechanisms in pancreatic cancer cell lines with the intent of identifying such an uptake mechanism and made the observation that a low-affinity, high-capacity, poorly-selective uptake protein, known as PepT1, was over-expressed on these cells (19) . Thus, a rationale exists to search for either small peptide-like agents that might enter cancer cells through PepT1 and block slug-mediated suppression of the OCLN promoter or for small molecules that could re-activate OCLN expression. Once reaching epithelial cancer cells, the agent would induce functional TJ structures to be re-established, leading to suppression of cancer cell growth and potentially an increased susceptibility to chemotherapeutic agents (Fig. 2) . 
Validation of Slug-E-box Binding Assay. A method to monitor Slug binding to the E-
box domain promoter region of OCLN was validated through a series of positive and negative control studies ( Table 1) . As a positive control, biotin-labeled E-box oligoduplex of OCLN promoter DNA was incubated with a Slug-green fluorescent proteins (GFP) protein chimera (Fig. 3) . Complexes formed in solution were captured on surfaces conjugated with streptavidin and detected using a horseradish peroxidase (HRP) conjugated antibody that recognized GFP; a signal that could be reduced by the inclusion of an equal amount of E-box DNA lacking biotin (Table 1 ). In addition, assay output signals were independent of addition sequence for biotin-labeled or unlabeled forms of OCLN E-box DNA when mixing with Slug-GFP, suggesting that the interaction between OCLN E-box DNA and Slug is dynamic and thus reversible (data not shown). To verify specificity, Slug-GFP was incubated with two different mutant forms of biotinlabeled occludin E-box oligos (Table 1) . For a constant amount of OCLN E-box sequence DNA, Slug-GFP bound in a dose-dependent manner; saturated binding occurred at ~8 μg, a ratio that was used in all subsequent studies ( Table 2) . were panned using biotin-labeled OCLN E-box DNA (Table 1) . Three rounds of panning were carried out in each screen with the Ph.D.-12 library being screened once and the Ph.D.-7 library being screened twice. Subtraction for E-box specificity was performed by a binding step using biotin-labeled DNA sequence containing a mutant E-box sequence shown not to interact with Slug (17) . Ten individual phages from the third round of each panning were propagated with DNA encoding the insert in the fusion protein (pVIII) being sequenced and translated into amino acid sequences (Table 3 ).
There were significant variations in the amino acid sequences that selectively bound
to OCLN E-box DNA, although some sequences were enriched with a frequency as high as 30%. Closer inspection, however, was used to identify short peptide sequences of 2-5 amino acids that repeated within the 7-or 12-amino acid phage libraries as well as between these libraries. These similarities are highlighted with underlining (Table 3) . Table 3 . Peptide sequences identified through Phage panning that bind to the OCLN Ebox sequence.
Library Peptide sequence Frequency
Ph.D. (Table 3) . Other amino acids sequences repeated within sequences phage were Arg-Arg (20%), Ala-Pro-Thr-XVal (10%), Lys-Val-Trp (10%), and Pro-Pro (10%). Together, this data set is consistent with the idea that a defined set of structures exists within the OCLN E-box DNA that can be selectively targeted through distinct peptide sequences.
Inhibition of Slug binding to E-box oligoduplex.
To determine whether peptides selected by phage display outcomes could inhibit Slug binding to the OCLN E-box, three peptides with the sequences Thr-Phe-Iso-Asp-Tyr-Pro-Val-Leu-Ser (TFIDYPVLS),
Lys-Cys-Cys-Phe-Pro-Iso-Ser-Thr-Glu (KCCFPISTE), and Gln-Pro-Pro-Thr-Val-Ser-Val-SerLys (QPPTVSVSK) were synthesized ( Table 3 ). The peptide Iso-Glu-Asp-Gly-Ser-Val-GlyLeu-Ala (IEDGSVGLA) was used as a negative control (Fig. 3) . About 65% of Slug binding to target DNA was blocked by TFIDYPVLS or KCCFPISTE but only a 42 % reduction in Slug binding resulted in the presence of QPPTVSVSK (Fig. 3) . Interestingly, others peptides synthesized that emulated the zinc finger domains of Slug {Stegmann, 1999
#60} only reduced GPF-Slug binding by ~30% (data not shown). (Table 4) .
Identification of
Several other compounds were identified in the screen out-performed 20 μM PD98059 when tested at 100 μM but failed to have an effect when tested at 10 μM. Another cadre of molecules induced MET morphology change and growth suppression without producing an effect on luciferase expression greater than that observed for PD98059.
This screening approach was unbiased toward mechanism of action. Most compounds identified at hits had the ability to induce morphology changes consistent with MET and growth suppression which correlated well with re-activation OCLN promoter function. A few molecules with growth suppressive function did not correlate with OCLN activation; this group of compounds was not pursued further. and cancer cell growth at 10 μM but did so when tested at 100 μM were smaller, simpler compounds than the first group. Except in one case, these smaller, less active compounds also contained an aromatic structure and either a methyl and carboxyl group. Importantly, the size and nature of compounds identified in this screen were amenable for modification to become selective substrates for hPepT1.
DISCUSSION
Herein we describe the rationale behind a novel approach to improve the selectivity and targeting of molecules that could induce an MET event in epithelial cancer cells and take initial steps toward the validation of that approach. In some ways, this approach is similar to that proposed by others who have examined genes associated with EMT events as a strategy to identify possible therapeutic targets for treating ductal pancreatic adenocarcinoma (28 that retain the ability to block Slug/E-box motif interactions will be identified through a rational design approach based upon these peptide sequences identified in this screen.
A second screen employed a Raf1-driven epithelial cell with an inserted reporter chimera gene that allowed for the expression of luminescence signal following reactivation of OCLN promoter function. Not being focused to a particular element of the dynamic established between the Ras/Raf/MEK/ERK pathway and the Ocln protein, this screen led to the identification of compounds from a chemical library whose mechanism of action would be unknown. The unbiased outcomes from this screen could be grouped into two categories: those that affected MET and cancer cell growth at 10 μM and those that produced these same outcomes but only at higher concentrations, in this case 100 μM. Subsequent studies will involve making a series of modifications to these hits to indentify critical elements for function in order to develop potential lead candidates.
Overall, these studies have described not only a strategy to identify a novel class of anti-cancer agents but provided in vitro evidence that cancer cells can be affected by molecules identified through these screening strategies. These screens were performed with the intent of identifying hits that could be developed into potential lead candidates. To identify these leads, we will combine information obtained from peptide sequences capable of blocking Slug binding to the OCLN promoter E-box with that of small molecule compounds identified from an NCI chemical library. The approach described represents a unique strategy where a selective uptake pathway up-regulated in cancer cells driven by a particular oncogene pathway is integrated into the lead development as a means of targeting the delivery of compounds that functionally block an MET suppression system. In this case, we have used the specific relationship between the Ras/Raf/MEK/ERK pathway and the TJ protein Ocln to allow for the selective targeting and reversal of EMT processes. Once cells revert via MET phenotype changes, we believe they may 1) stop growing aggressively with a reduced potential for metastasis (1, 14) , and 2) be more susceptible to stress agents currently being tested as chemotherapeutics. The dynamic used in our studies should be useful to treat epithelial cancers derived from the pancreas, stomach, and prostate where up-regulation of the Ras/Raf/MEK/ERK pathway can be confirmed. It is possible that other cancer cells may be similarly targeted and treated via other dynamics established to control EMT↔MET events, such as those involving the PI3K/PTEN/Akt/mTOR pathway (6, 31). 
TABLES
